In the latest trading session, Moderna (MRNA) closed at $174.30, marking a -1% move from the previous day.
Novavax (NASDAQ: NVAX) has offered investors just such a ride over the past few years. Initial gains came as investors bet on Novavax's chances of bringing a coronavirus vaccine to market; declines occurred after the vaccine entered the market later than rival products did. Now, as we start a new year, you might be wondering what to do about Novavax.
The bad news is Moderna's vaccine may not be able to replicate these levels in a post-pandemic environment. The good news is the vaccine still could lead to significant blockbuster revenue -- and that will support the development of Moderna's late-stage pipeline. As a result, Moderna could launch other potential blockbusters over the next few years.